MiReven Announces Positive Preclinical Results for miR-7 in Head and Neck Cancer

MiReven, an Australian microRNA company commercialising discoveries from the Western Australian Institute for Medical Research (WAIMR) on the anti-cancer potential of miR-7, today announced the publication in the journal PLOS One of a study in which miR-7 was examined in combination with the head and neck cancer (HNC) treatment erlotinib hydrochloride (Tarceva, Genentech/OSIP).

Read full article

Avatar for cwraight

Subscribe

Subscribe to our e-mail newsletter to receive updates.

Comments are closed.